Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,621 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,498 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00294476 | IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma | unknown | Phase 2 | 30 | GammaCanINDUSTRY | 1 | Oct 12, 2006 | clinicaltrials |
| NCT00165867 | An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin | completed | Phase 2 | 40 | Eisai LimitedINDUSTRY | 2 | Oct 9, 2006 | clinicaltrials |
| NCT00176761 | Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine | terminated | Phase 2 | 27 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 11, 2006 | clinicaltrials |
| NCT00108875 | Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer | unknown | Phase 1 / Phase 2 | 70 | Julius-Maximilians UniversityOTHER | 1 | Jul 28, 2006 | clinicaltrials |
| NCT00356161 | HAI Via Interventionally Implanted Port Catheter Systems | unknown | Phase 2 | 100 | Charite University, Berlin, GermanyOTHER | 1 | Jul 25, 2006 | clinicaltrials |
| NCT00034502 | A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. | completed | Phase 1 / Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 2 | Jul 19, 2006 | clinicaltrials |
| NCT00034619 | A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2006 | clinicaltrials |
| NCT00209703 | Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer | terminated | Phase 2 | 30 | Hokkaido Gastrointestinal Cancer Study GroupOTHER | 1 | Apr 21, 2006 | clinicaltrials |
| NCT00197431 | Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer | unknown | Phase 2 | — | Hamamatsu UniversityOTHER | 1 | Mar 22, 2006 | clinicaltrials |
| NCT00209625 | Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 23 | Hokkaido Gastrointestinal Cancer Study GroupOTHER | 1 | Sep 21, 2005 | clinicaltrials |
| NCT00154713 | Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment | unknown | Phase 1 / Phase 2 | 37 | National Taiwan University HospitalOTHER | 1 | Sep 12, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Oct 12, 2006source: clinicaltrials